NEW YORK–(BUSINESS WIRE)–#AIPrecisionMedicine–Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast CTX, a new predictive capability within its Ataraxis Breast platform, designed to help estimate individualized chemotherapy benefit in breast cancer patients.
Ataraxis Breast combines digitized H&E pathology slides with clinical data to generate prognostic and predictive patient-specific predictions that support treatment decision-making. With Ataraxis Breast CTX, the platform predicts patient-level outcomes under two treatment strategies, with and without adjuvant chemotherapy. This prediction is enabled by Ataraxis™ Tau, the company’s causal inference layer designed to account for treatment selection bias and confounding commonly present in retrospective and real-world datasets.
The test was developed using multimodal data from over 10,000 breast cancer patients worldwide and independently validated across observational real-world studies and randomized controlled trials. Since its launch, Ataraxis Breast CTX has been adopted by top NCI-designated cancer centers and community clinics across the United States.
“For too long, chemotherapy decisions in breast cancer have been based on how a treatment works on average, not whether it will actually benefit the specific person sitting across from you. Ataraxis Breast CTX was built to change that. It is a first-in-class test, not just best-in-class, because no tool has estimated individualized chemotherapy benefit this way before. At its core is Ataraxis Tau, our causal AI layer, which is what makes this possible. CTX is the first in what we’re building as a new generation of predictive tools, each one bringing us closer to our vision of fully personalized cancer care.” – Jan Witowski MD PhD, CEO & co-founder, Ataraxis AI
Ataraxis™ Tau
Ataraxis Tau is the causal AI platform behind Ataraxis predictive tools. It enables estimation of treatment benefit by modeling how therapies influence outcomes at the individual patient level, while adjusting for underlying risk factors. By separating prognosis from treatment effect, Tau makes it possible to move beyond population averages toward truly personalized predictions. It serves as the platform on which a new generation of predictive tests is being built.
Moving Beyond Risk Alone
In early-stage breast cancer, treatment decisions are often guided by recurrence risk. Today, that risk is typically assessed using basic clinicopathologic factors or genomic assays with limited accuracy and scope, while therapy selection is largely based on how treatments perform on average in similar patient populations rather than on individualized predictions of benefit.
The Ataraxis Breast platform was built to improve both parts of this decision. Ataraxis Breast includes RISK, an AI-based prognostic test validated for use in all molecular subtypes, including HER2-positive and triple-negative breast cancer (TNBC) patients, extending recurrence risk assessment to populations often not addressed by legacy tools.
Ataraxis Breast CTX is the first predictive tool offered by Ataraxis. It follows RISK and estimates chemotherapy benefit by separating baseline prognosis from treatment effect, helping clinicians better understand how an individual patient may respond to therapy. Together, RISK and CTX support a more individualized approach to treatment planning.
This individualized approach can also help address a persistent challenge in breast cancer care: overtreatment driven by average-based assumptions. By estimating chemotherapy benefit at the patient level, CTX can help identify a clinically important subgroup of patients who appear high risk for recurrence yet are unlikely to derive meaningful benefit from adjuvant chemotherapy, supporting more informed decisions and helping clinicians consider alternative strategies when appropriate.
About Ataraxis AI
Ataraxis AI is a precision oncology company building AI-powered tools to personalize cancer care. By integrating routine digital pathology with clinical data, Ataraxis aims to deliver individualized insights into prognosis and treatment benefit across multiple cancer types. To learn more, visit ataraxis.ai.
Ataraxis™ Breast is Ataraxis AI’s flagship multimodal platform for breast cancer. Delivered as a suite of AI-powered clinical tests, it combines routine digital pathology with clinical data to generate predictions of recurrence risk and therapy response, supporting decision-making across the full continuum of care. The Ataraxis Breast platform was developed using 20,000+ multimodal patient cases and is designed to fit into existing pathology workflows without requiring additional tissue or specialized assays. All Ataraxis Breast tests are offered as laboratory-developed tests through a CLIA-certified laboratory.
Contacts
Media: [email protected]
